MILAN (Reuters) – Italian medical diagnostic group Diasorin announced Tuesday that it plans to launch a new serological test to detect antibodies in patients infected with the new coronavirus by the end of April.
Diasorin said it has completed its studies and is striving to obtain the EU CE marking system and clearance from the US Food and Drug Administration (FDA) by the end of this month.
Several university laboratories and medical companies are rushing to produce these blood tests, which can quickly identify anti-disease antibodies in people who are already infected.
“The product was designed to meet the need to identify people in the population who have already been infected with the virus, where the diagnosis was not made with a swab and a molecular diagnostic test,” said Diasorin in a press release.
Diasorin has already launched a molecular test to quickly identify the new coronavirus.
Six weeks after the coronavirus outbreak in the country, authorities in northern Italy began testing health workers for antibodies that could help identify people immune to the virus as they search for ways to reduce the lockdown imposed a month ago to contain the epidemic.
Diasorin shares increased by more than 6% in the first exchanges.
Report by Elisa Anzolin; edited by Jason Neely
Our standards:Principles of the Thomson Reuters Trust.